SCHEMBL922002

SCHEMBL922002

CC(=O)/C(=N/Nc1ccccc1)C(=O)NC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.49
MAPT P10636 7/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 3/20 0.47
NPC1 O15118 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 1/20 0.45
GAA P10253 6/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
CYP2C9 P11712 1/20 0.43
RECQL P46063 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 5/20 0.42
TDP1 Q9NUW8 1/20 0.39
ALPL P05186 1/20 0.38
ALPI P09923 1/20 0.38
ALPG P10696 1/20 0.38
NAPRT Q6XQN6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922004 1.00 GFER (0.49) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL519257 0.83 MAPT (0.56) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7487444 0.82 GFER (0.69) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7487450 0.82 GFER (0.69) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7490755 0.80 MAPT (0.54) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7490754 0.80 MAPT (0.54) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7487475 0.77 MAPT (0.51) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7487469 0.77 MAPT (0.51) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7490040 0.76 MAPT (0.48) GFERMAPTRAB9ASMN1; SMN2MAPK1
SCHEMBL7490045 0.76 MAPT (0.48) GFERMAPTRAB9ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 GFER 3672/4885MAPT 4573/4885RAB9A 4545/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 GFER 3672/4885MAPT 4573/4885RAB9A 4545/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC GFER 4744/4885MAPT 4000/4885RAB9A 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.